TherapeuticsMD ( (TXMD) ) has shared an announcement.
TherapeuticsMD reported a net loss from continuing operations of $2.3 million for the year ending December 31, 2024, a significant improvement from the previous year’s loss of $7.7 million. The company experienced a 35.3% increase in license revenue, primarily due to the Mayne License Agreement, and reduced its operating expenses by 33.6% as it continues to transition from a commercial business to a royalty-based model. TherapeuticsMD is also exploring strategic alternatives, including potential mergers or acquisitions, though no specific outcomes or timelines have been established.
More about TherapeuticsMD
TherapeuticsMD, Inc., previously a women’s healthcare company, has transitioned into a pharmaceutical royalty company, focusing on collecting royalties from its licensees. The company no longer engages in research and development or commercial operations.
YTD Price Performance: -35.67%
Average Trading Volume: 589,996
Technical Sentiment Signal: Buy
Current Market Cap: $11.65M
Find detailed analytics on TXMD stock on TipRanks’ Stock Analysis page.